4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.18
-0.05 (-0.54%)
Mar 24, 2026, 4:00 PM EDT - Market closed
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover 4D Molecular Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $33.5, which forecasts a 264.92% increase in the stock price over the next year. The lowest target is $26 and the highest is $38.
Price Target: $33.5 (+264.92%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +292.16% | Mar 20, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $32 → $35 | Buy | Maintains | $32 → $35 | +281.26% | Mar 19, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $26 | Strong Buy | Maintains | $26 | +183.22% | Mar 19, 2026 |
| Barclays | Barclays | Buy Initiates $33 | Buy | Initiates | $33 | +259.48% | Jan 28, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $26 | Strong Buy | Maintains | $26 | +183.22% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
20.66M
from 85.21M
Decreased by -75.75%
Revenue Next Year
21.76M
from 20.66M
Increased by 5.28%
EPS This Year
-3.55
from -2.42
EPS Next Year
-3.52
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 53.9M | 33.6M | |||
| Avg | 20.7M | 21.8M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -36.8% | 62.6% | |||
| Avg | -75.7% | 5.3% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.73 | -1.44 | |||
| Avg | -3.55 | -3.52 | |||
| Low | -4.21 | -4.85 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.